Logo

BioMarin's Palynziq (pegvaliase-pqpz) Receives FDA Approval for Phenylketonuria (PKU) in Adults

Share this

BioMarin's Palynziq (pegvaliase-pqpz) Receives FDA Approval for Phenylketonuria (PKU) in Adults

Shots:

  • The approval is based on P-III PRISM-2 study results assessing Palynziq (pegvaliase-pqpz- 20mg qd or 40mg qd) in patients in ratio (2:1) with high level of phenylalanine (Phe)
  • The P-III PRISM-2 study resulted in maintaining blood Phe level vs PBO in patients
  • Palynziq (pegvaliase-pqpz- SC) is an enzyme substitution therapy of phenylalanine hydroxylase (PAH) enzyme helping in breaking down of Phe

Ref: Biomarin | Image: Biomarin

 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions